Alto Neuroscience (NYSE:ANRO) Upgraded at Wall Street Zen

Alto Neuroscience (NYSE:ANRO) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other equities research analysts have also recently weighed in on the stock. Jefferies Financial Group raised their target price on shares of Alto Neuroscience from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, October 8th. HC Wainwright increased their price target on Alto Neuroscience from $10.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 24th. Chardan Capital assumed coverage on Alto Neuroscience in a report on Monday, September 29th. They issued a “buy” rating and a $15.00 price objective for the company. Finally, Robert W. Baird increased their target price on Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a report on Thursday. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.20.

Alto Neuroscience Stock Performance

NYSE:ANRO opened at $12.01 on Friday. The firm has a market capitalization of $373.21 million, a P/E ratio of -5.25 and a beta of 2.90. Alto Neuroscience has a twelve month low of $1.60 and a twelve month high of $15.18. The company has a fifty day moving average of $7.71 and a 200-day moving average of $4.51. The company has a quick ratio of 18.43, a current ratio of 15.42 and a debt-to-equity ratio of 0.20.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.14. As a group, sell-side analysts anticipate that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Trading of Alto Neuroscience

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP grew its stake in shares of Alto Neuroscience by 160.6% during the third quarter. Two Sigma Investments LP now owns 116,579 shares of the company’s stock valued at $469,000 after buying an additional 71,844 shares during the last quarter. Bridgeway Capital Management LLC lifted its stake in shares of Alto Neuroscience by 43.5% during the 3rd quarter. Bridgeway Capital Management LLC now owns 77,653 shares of the company’s stock worth $312,000 after acquiring an additional 23,553 shares during the last quarter. Peapod Lane Capital LLC boosted its holdings in Alto Neuroscience by 1.1% during the 3rd quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company’s stock valued at $1,136,000 after acquiring an additional 3,106 shares during the period. Vanguard Group Inc. boosted its holdings in Alto Neuroscience by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,105,407 shares of the company’s stock valued at $4,444,000 after acquiring an additional 20,702 shares during the period. Finally, Vanguard Personalized Indexing Management LLC grew its position in Alto Neuroscience by 13.7% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after acquiring an additional 2,055 shares during the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.